Table 1.

Summary of models of neurodegeneration and the reported effects on neurogenesis (NPC: neural precursor cell; PS1: presinilin-1; SGZ: subgranular zone; SVZ: subventricular zone; DG: dentate gyrus; AD: Alzheimer’s Disease; PD: Parkinson’s Disease; 6-OHDA: 6-hydroxydopamine; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).

Model of Neurodegeneration	Effect on Neurogenesis
NPCs from mice expressing the PS1 variant co-cultured with PS1-expressing microglia [212]	Decreased proliferation and differentiation
Mice with familial PS1 A246E mutation [213]	Increased proliferation of NPCs in the SGZ, no effect on survival and differentiation
Mice with mutated form of APP [214]	Decreased proliferation and survival of NPCs in the DG
Mice with PDGF-APPSw,Ind mutation [215]	Two fold enhancement in proliferation in both the DG and SVZ
AD human patients [216]	Increased proliferation and differentiation in the DG
AD human patients [210]	Decreased proliferation and survival in the DG
Mice with PDAPP mutation [217]	Age-dependent decrease in proliferation in the SGZ
Administration of Aβ1–42 in vitro [218]	Increased proliferation in the SVZ
3xTg-AD mice [219,220]	Age-dependent decrease in neurogenesis in the SGZ
APP/PS1 mice [224]	Decreased neurogenesis in the SGZ
APP/PS1 mice treated with minocycline [199]	Increased survival in the SGZ, no effect on cell proliferation and differentiation
Overexpression of human wild-type α-synuclein model of PD in mice [231]	Decreased survival in the SGZ
MPTP model of PD in mice [232]	Decreased proliferation in the SVZ
6-OHDA model of PD in rats [232]	Decreased proliferation in the SVZ
PD human patients [233]	Decreased proliferation in the SGZ
PD human patients [234]	Decreased proliferation in the SVZ
MPTP model of PD in mice [235]	Transient increase in proliferation in the SGZ
6-OHDA model of PD in rats [236]	No effect on proliferation or differentiation in the SGZ
MPTP model of PD in mice [237]	Decreased proliferation in the SVZ